Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) FCF Margin (2017 - 2026)

Neurocrine Biosciences filings provide 15 years of FCF Margin readings, the most recent being 48.02% for Q4 2025.

  • On a quarterly basis, FCF Margin rose 481.0% to 48.02% in Q4 2025 year-over-year; TTM through Dec 2025 was 27.29%, a 210.0% increase, with the full-year FY2025 number at 27.29%, up 210.0% from a year prior.
  • FCF Margin hit 48.02% in Q4 2025 for Neurocrine Biosciences, up from 31.46% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 646.5% in Q2 2022 to a low of 29.92% in Q1 2023.
  • Median FCF Margin over the past 5 years was 28.72% (2023), compared with a mean of 53.11%.
  • Biggest five-year swings in FCF Margin: soared 61227bps in 2022 and later plummeted -60687bps in 2023.
  • Neurocrine Biosciences' FCF Margin stood at 0.83% in 2021, then soared by 3605bps to 30.87% in 2022, then decreased by -10bps to 27.93% in 2023, then surged by 55bps to 43.21% in 2024, then increased by 11bps to 48.02% in 2025.
  • The last three reported values for FCF Margin were 48.02% (Q4 2025), 31.46% (Q3 2025), and 13.02% (Q2 2025) per Business Quant data.